Piper Sandler Trims Immunic (NASDAQ:IMUX) Target Price to $39.00

Immunic (NASDAQ:IMUXGet Rating) had its price objective reduced by Piper Sandler from $71.00 to $39.00 in a research report sent to investors on Tuesday morning, The Fly reports. Piper Sandler currently has an overweight rating on the stock.

IMUX has been the subject of several other research reports. Zacks Investment Research downgraded shares of Immunic from a hold rating to a sell rating in a research report on Tuesday, May 3rd. Wedbush reiterated an outperform rating on shares of Immunic in a report on Friday, May 6th. Finally, StockNews.com initiated coverage on shares of Immunic in a research note on Thursday, March 31st. They issued a sell rating on the stock. Two equities research analysts have rated the stock with a sell rating and three have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of Hold and an average target price of $34.50.

Shares of NASDAQ IMUX opened at $5.48 on Tuesday. The firm has a market cap of $167.36 million, a price-to-earnings ratio of -1.75 and a beta of 1.99. Immunic has a 52-week low of $4.96 and a 52-week high of $15.12. The company’s 50-day simple moving average is $9.17 and its 200-day simple moving average is $10.09.

Immunic (NASDAQ:IMUXGet Rating) last announced its quarterly earnings data on Thursday, February 24th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.08). During the same quarter in the previous year, the business posted ($0.46) EPS. Equities analysts expect that Immunic will post -3.01 EPS for the current fiscal year.

In other Immunic news, Chairman Duane Nash bought 10,000 shares of the stock in a transaction on Thursday, May 12th. The shares were bought at an average price of $5.03 per share, with a total value of $50,300.00. Following the purchase, the chairman now directly owns 22,032 shares in the company, valued at approximately $110,820.96. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders purchased a total of 20,000 shares of company stock worth $101,240 in the last three months. 12.07% of the stock is currently owned by company insiders.

Several hedge funds have recently made changes to their positions in IMUX. RTW Investments LP lifted its stake in Immunic by 57.7% in the first quarter. RTW Investments LP now owns 2,705,513 shares of the company’s stock valued at $30,572,000 after buying an additional 990,043 shares during the period. Point72 Asset Management L.P. bought a new position in shares of Immunic during the 3rd quarter worth approximately $5,531,000. Parkman Healthcare Partners LLC boosted its stake in Immunic by 123.2% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 924,087 shares of the company’s stock valued at $8,178,000 after purchasing an additional 510,000 shares during the period. Sphera Funds Management LTD. bought a new stake in Immunic in the 3rd quarter valued at $3,450,000. Finally, Altium Capital Management LP lifted its position in shares of Immunic by 890.0% during the 4th quarter. Altium Capital Management LP now owns 317,000 shares of the company’s stock valued at $3,034,000 after acquiring an additional 284,979 shares during the period. Institutional investors own 49.03% of the company’s stock.

About Immunic (Get Rating)

Immunic, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease.

Read More

The Fly logo

Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.